Q4 2024 Revenue: $164,000, down from $299,000 in Q4 2023. Full Year 2024 Revenue: $515,000, down from $11 million in 2023. Q4 2024 Cost of Revenue: $272,000, down from $773,000 in Q4 2023. Full Year 2024 Cost of Revenue: $1.6 million, down from $2 million in 2023. Q4 2024 Gross Loss: $108,000, compared to $474,000 in Q4 2023. Full Year 2024 Gross Loss: $1.1 million, compared to a gross profit of $9 million in 2023. Q4 2024 Operating Expenses: $3.9 million, down from $4.6 million in Q4 2023. Full Year 2024 Operating Expenses: $16.1 million, down from $16.5 million in 2023. Q4 2024 Net Loss: $3.9 million or $0.34 per share, compared to $4.7 million or $0.41 per share in Q4 2023. Full Year 2024 Net Loss: $16.6 million or $1.45 per share, compared to $7 million or $0.62 per share in 2023. Cash and Cash Equivalents (Dec 31, 2024): $11.9 million. Cash Used in Operating Activities (2024): $14.1 million, compared to $2.8 million in 2023. Cash Used in Investing Activities (2024): $539,000, compared to $1.2 million provided in 2023. Cash Provided by Financing Activities (2024): $9,000, compared to $1.1 million in 2023.

Warning! GuruFocus has detected 4 Warning Signs with CLGN.

Release Date: March 26, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

CollPlant Biotechnologies Ltd (NASDAQ:CLGN) is advancing its proprietary photocurable dermal filler, which is in the preclinical phase and targets a market valued at approximately $6.3 billion with a 10% compound annual growth rate. The company has received positive feedback from thought leaders in aesthetic medicine regarding its photocurable dermal filler, suggesting it could be a game changer for facial plastic surgery. CollPlant's collaboration with AbbVie is progressing, with AbbVie collecting data from clinical trials and a recent $2 million payment received by CollPlant following a development achievement. The regenerative breast implant program is showing promising preclinical results, with successful tissue integration and vascularization observed in one study arm. CollPlant's recombinant human collagen technology is in demand, with ongoing discussions with various companies interested in accessing this technology.

Negative Points

CollPlant Biotechnologies Ltd (NASDAQ:CLGN) reported a significant decrease in GAAP revenues for 2024, with $515,000 compared to $11 million in 2023, primarily due to a $10 million milestone payment from AbbVie in 2023. The company experienced a GAAP gross loss of $1.1 million for the year ended December 31, 2024, compared to a gross profit of $9 million in 2023. GAAP net loss for 2024 was $16.6 million, significantly higher than the $7 million net loss in 2023, attributed to the absence of a large milestone payment received in the previous year. Cash used in operating activities increased to $14.1 million in 2024 from $2.8 million in 2023, indicating higher operational expenses. The company's cash runway is expected to last only until the second quarter of 2026, raising concerns about long-term financial sustainability without additional revenue streams or partnerships.

Story Continues

Q & A Highlights

Q: When can we expect an update from AbbVie on their studies, and are there any anticipated milestone payments in 2025? A: AbbVie is currently reviewing interim results from the first cohort of patients in their dermal filler clinical trials. The next steps will be determined by AbbVie, and we will update the market accordingly. Recently, we received a $2 million payment from AbbVie following a development achievement, but we cannot estimate when the next milestone payment will occur. - Eran Rotem, Deputy CEO and CFO

Q: Can you provide details on the market potential and revenue expectations for the VergenixSTR product in Europe and Asia? A: VergenixSTR is intended for treating tendinopathy and has a market potential of 1% to 3% of the population. We are establishing a distribution network in Europe and Asia, and each country requires regulatory approval. We expect to start seeing sales next year, with the product offering a significant advantage over steroid injections. - Yehiel Tal, CEO

Q: What is the company's current cash position and burn rate, and how long will it last? A: As of December 31, 2024, we had $11.9 million in cash, not including a recent $2 million payment from AbbVie. Our cost reduction plan does not materially impact main development programs. We expect our cash to support operations through the second quarter of 2026, under conservative assumptions. - Eran Rotem, Deputy CEO and CFO

Q: What are the upcoming catalysts for CollPlant's proprietary programs? A: We plan to potentially launch a clinical trial for our photocurable dermal and soft tissue filler within two years. For our regenerative breast implant program, we aim to optimize the implant characteristics and clinical protocol to reach clinical trial readiness. We will also expand the distribution network for VergenixSTR in Europe and Asia and broaden our bioinks product offerings. - Yehiel Tal, CEO

Q: How is CollPlant planning to expand sales of its rhCollagen product? A: We plan to expand sales of our rhCollagen to selected customers that align with our business model. This expansion is part of our strategy to support various bioprinting technologies and advance potential partnership discussions. - Yehiel Tal, CEO

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments